[Frontiers in Bioscience E3, 1310-1314, June 1, 2011]
The effect of pharmacological treatment on ADMA in patients with heart failure
Graziano Riccioni1, Lorenza Speranza2, Luca Scotti3, Valentina Bucciarelli3, Emanuela Di Ilio3, Nicolantonio D'Orazio4, Mirko Pesce2, Antonio Aceto3, Valeria Sorrenti5, Alessandro Frigiola6, Tonino Bucciarelli3
1Cardiology Unit, San Camillo de Lellis Hospital, Manfredonia, Foggia, Italy, 2Biology Institute, University, G. D'Annunzio, Chieti, Italy, 3Clinical Biochemistry, Department of Biomedical Science, University, G. D'Annunzio, Chieti, Italy, 4Human Nutrition, Department of Biochemical Sciences, University, G. D'Annunzio, Chieti, Italy,5Medical Chemistry and Molecular Biology, Department of Biological Chemistry, University of Catania, Italy ,6Department of Cardiac Surgery, IRCCS Policlinico S. Donato, Via Morandi 30, San Donato Milanese, Milan, Italy
TABLE OF CONTENTS
Asymmetric dimethylarginine (ADMA) plays a crucial role in the arginine-nitric oxide (NO) pathway. NO plays an important role in controlling vascular tone and regulates the contractile properties of cardiac myocytes. The purpose of this study was to investigate the effect of pharmacological treatment on asymmetrical dimethylarginine (ADMA) plasma levels in patients with acute congestive heart failure (HF). Patients with symptomatic acute congestive HF (NYHA Class III-IV) and impaired left ventricular (LV) function (ejection fraction < 40%) were included in the study. ADMA and SDMA concentrations were assessed before and after pharmacological treatment in 18 critically ill patients on the intensive care unit by high performance liquid chromatography. All patients received a complete pharmacological treatment (diuretics, digoxin, ACE-inhibitors or angiotensin receptor blockers, and nitroglicerin) for the treatment of acute congestive HF. ADMA plasma levels of critically ill patients were significantly higher after pharmacological treatment respect baseline values (pre-treatment). In critically ill patients with acute congestive HF acute renal impairment function and the modulation of NOS determine plasma ADMA/SDMA levels after therapy.